by jtierney | May 31, 2026 | Press Releases
100% ORR and MRD-negative responses observed in all evaluable patients, earliest dosed patients remain in ongoing MRD negative response beyond 9 months Favorable safety profile consistent with outpatient dosing 13-day median time from consent to infusion CAR-T cell...
by jtierney | May 21, 2026 | Press Releases
Company also announces Fast Track Designation from FDA for investigational candidate KLN-1010 in relapsed and refractory multiple myeloma BOSTON, Mass., May 21, 2026– Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in...
by jtierney | Apr 20, 2026 | Press Releases
Kelonia’s lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted in the 2025 ASH Annual Meeting plenary session Acquisition...
by jtierney | Jan 7, 2026 | Press Releases
U.S. IND represents the second regulatory clearance for KLN-1010 and enables the first multi-center clinical trial in the U.S. for an anti-BCMA in vivo CAR-T program BOSTON,...
by jtierney | Dec 9, 2025 | Press Releases
100% MRD-negative response rate in four patients; all remain in response through the longest follow up of 5 months Favorable toxicity profile with no CRS grade 3 or above and no ICANS Potent CAR-T expansion from a single, an off-the-shelf infusion without...